BioSpace News Archive

The National Comprehensive Cancer Network ® ( NCCN ® ) Oncology Research Program ( ORP ) today announced plans to evaluate neratinib, a type of tyrosine kinase inhibitor (TKI) that works as a dual

Partek Incorporated announced today that its software has been cited in over eight thousand peer-reviewed articles published in scientific journals, including the prestigious PNAS , Cell , and Nature Medicine journals. Topics throughout their twenty-seven-year history

Tenax gains developmental and commercial rights for a fully-developed oral levosimendan formulation in the U.S. and Canada Oral formulation expected to be used in upcoming Phase 3 registration trial

Abiomed, Inc . (NASDAQ: ABMD) announced it will host a virtual investor meeting on Tuesday, October 20, 2020 at 8:00 a.m. EDT to review new clinical data presented at TCT Connect , the 32nd annual scientific symposium of the Cardiovascular Research Foundation. The virtual meeting will include a presentation from Chuck A. Simonton, MD, Vice President and Chief Medical Officer, focused on the latest data from the PROTECT

ValueSetters, Inc. (OTC:VSTR) announced that the company will partner with Vymedic to advance its innovative, patented approach to helping millions impacted by influenza, the common cold and other viruses. As an indication of its high conviction in the company, ValueSetters has taken an equity ownersh

Cellaria, Inc. (Wakefield, MA, USA), a scientific innovator with breakthrough tools for cancer research, has introduced three next generation Pancreatic Cancer cell lines, substantially boosting the value of in vitro methods in the development of more effective therapies. Difficult to detect

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced it has partnered with EVERSANA™, a leading provider of commercial services to the life science industry, to

On September 23rd, the FDA announced the highest level of alert about benzodiazepines when it required a boxed warning for all of these medications.

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it has been included in the 32nd annual Growth List, the definitive ranking of Canada’s Fastest-Growing Companies by Canadian Business and Maclean’s.

OS Therapies, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat and cure Osteosarcoma (OS) and other deadly cancers in children and adults, today announced that they have initiated their sponsorship of the FDA Investigational New Drug (IND) application for OST-HER2 a